Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on August 25, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). FDA approval expands Ziihera into first-line HER2+ gastroesophageal adenocarcinoma treatment.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA approval expands Ziihera into first-line HER2+ gastroesophageal adenocarcinoma treatment
- Two regimens approved, including combination with Jazz’s Tevimbra and chemotherapy
- Indications cover unresectable locally advanced or metastatic disease
- Approval supports potential commercial expansion for Zymeworks through its Jazz partnership
Item 8.01 · Other Events
- FDA approval of two first-line Ziihera regimens in HER2-positive GEA triggers Zymeworks’ $250 million milestone
- Up to $1.3 billion in additional regulatory and commercial milestones remains available
- Tiered royalties of 10%–20% on Jazz’s net sales in licensed territories create ongoing commercial upside
- Approval expands zanidatamab’s validated use in unresectable locally advanced or metastatic HER2-positive GEA
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.